Alpha Cognition Inc. (ACOG)
- Previous Close
8.69 - Open
8.65 - Bid 8.32 x 200
- Ask 9.50 x 100
- Day's Range
8.60 - 9.42 - 52 Week Range
3.75 - 11.40 - Volume
191,948 - Avg. Volume
91,877 - Market Cap (intraday)
146.421M - Beta (5Y Monthly) 2.49
- PE Ratio (TTM)
-- - EPS (TTM)
-1.28 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
31.18
Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer's disease. Its pre-clinical development programs comprise ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer's disease; ALPHA-1062 sublingual formulation for acute pancreatitis; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mild traumatic brain injury; and ALPHA-0602, ALPHA-0702, and ALPHA-0802 programs for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis disease and spinal muscular atrophy. The company was founded in 2000 and is headquartered in Vancouver, Canada.
www.alphacognition.comRecent News: ACOG
View MorePerformance Overview: ACOG
Trailing total returns as of 5/23/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ACOG
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ACOG
View MoreValuation Measures
Market Cap
146.42M
Enterprise Value
98.79M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
30.64
Price/Book (mrq)
3.59
Enterprise Value/Revenue
33.73
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-26.73%
Return on Equity (ttm)
-56.80%
Revenue (ttm)
2.93M
Net Income Avi to Common (ttm)
-11.64M
Diluted EPS (ttm)
-1.28
Balance Sheet and Cash Flow
Total Cash (mrq)
45.53M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-4.74M